secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001628280-24-012222
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat
--------------------------------------------------------------------------------

- Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.
- Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.
- Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.
- 2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.
- 10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/oabi-20240320.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer